<?xml version="1.0" encoding="UTF-8"?>
<p>Most RCTs evaluated interventions for infected subjects (661, 94%), while 37 RCTs (5%) evaluated prophylactic therapies. There were 423 studies (61%) that evaluated drugs, including hydroxychloroquine (122, 17%), lopinavir/ritonavir (36, 5%) and chloroquine (31, 4%). Other interventions included traditional Chinese medicines (84, 12%), biological agents (60, 9%), and vaccines (14, 2%).</p>
